VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
FATE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
FATEFate Therapeutics, Inc.
$3.02$352M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksFATEDividend History

FATE logoFate Therapeutics, Inc. (FATE) Dividend History

Income profile from 2011 to 2025 with payout safety and yield-on-cost trend

Trailing Dividend / Share
$0.00
0 payments in last 12 months
Dividend Yield
N/A
Current annualized yield
Payout Ratio
N/A
Unknown
Dividend Streak
0 years
Consecutive annual increases
5Y Dividend CAGRN/A
Current Yield on CostN/A
Yield on Cost Trendunknown

FATE Dividend Income Check

Safety

Payout ratio data not available yet.

Consistency

0 straight years of dividend increases.

Income Trend

Yield on cost trend needs more history.

FATE Dividend Scorecard

Yield & Income

Dividend YieldN/A
Trailing DPS$0.00
FrequencyN/A
Payments / 12M0

Payout Safety

Earnings PayoutN/A
Earnings SafetyUnknown
FCF PayoutN/A
FCF SafetyUnknown
Piotroski F-Score2/9

Growth

Growth Streak0 years
3Y CAGRN/A
5Y CAGRN/A
Yield on Cost (5Y)N/A
YOC Trendunknown

Total Returns

Buyback Yield0.0%
Total Shareholder Yield0.0%
1Y Total Return184.9%
5Y Total Return-96.5%
Estimated $10K growth (return + dividends):
5Y ago$24310Y ago$10,89920Y ago$3,112

Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). Different time windows can produce different outcomes depending on market regime and entry point.

FATE Dividend History

No dividend payment history available

This company has not paid dividends during the available data period.

Get FATE's next ex-dividend date and payout in your inbox

Monthly dividend calendar — upcoming ex-dates for stocks you follow.

Free. Unsubscribe any time.

Dividend Analysis

Payout Safety

Fate Therapeutics, Inc. has limited earnings payout data (Unknown).

Piotroski F-Score: 2/9 — weak financial health.

Growth Track Record

FATE does not have a current streak of consecutive dividend increases.

Total Shareholder Returns

Beyond cash dividends, FATE returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.

Income Trend & Total Return

The 5-year total return is -96.5%.

DRIP Growth

A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $10,899 today.

FATE Annual Dividend History (2011–2025)

15 years of dividend data

GrowthDecline
YearDPSYoYPmtsEPSPayoutCoverageFCF/ShareFCF PayoutBuyback YldTotal Shld YldYOC
2025$0.00—0$-1.15——$-0.94—0.0%0.0%—
2024$0.00—0$-1.64——$-1.09—0.0%0.0%—
2023$0.00—0$-1.64——$-1.41—0.0%0.0%—
2022$0.00—0$-2.91——$-2.93—0.0%0.0%—
2021$0.00—0$-2.24——$-2.25—0.0%0.0%—
2020$0.00—0$-2.10——$-0.54—0.0%0.0%—
2019$0.00—0$-1.43——$-1.33—0.0%0.0%—
2018$0.00—0$-1.19——$-0.73—0.0%0.0%—
2017$0.00—0$-1.02——$-0.92—0.0%0.0%—
2016$0.00—0$-1.05——$-0.95—0.0%0.0%—
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

FATE — Frequently Asked Questions

Quick answers to the most common questions about buying FATE stock.

How much dividend does FATE pay per share?

Fate Therapeutics, Inc. (FATE) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.

When is FATE's next ex-dividend date?

FATE's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. FATE typically pays dividends quarterly.

Is FATE's dividend safe?

FATE's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.

How many years has FATE increased its dividend?

FATE has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.

How often does FATE pay dividends?

Fate Therapeutics, Inc. pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 14+ years from 2011 to 2025.

How much would $10,000 invested in FATE grow with dividend reinvestment?

With dividends reinvested (DRIP), $10,000 invested in FATE five years ago would be worth approximately $243 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.

What is FATE's yield on cost for long-term holders?

FATE's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.